DaVita Inc. (NYSE:DVA) Short Interest Up 9.2% in January

DaVita Inc. (NYSE:DVA) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 4,410,000 shares, a growth of 9.2% from the December 31st total of 4,040,000 shares. Approximately 5.6% of the shares of the stock are short sold. Based on an average trading volume of 762,200 shares, the days-to-cover ratio is presently 5.8 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its stake in shares of DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares during the last quarter. Glenmede Trust Co. NA grew its position in shares of DaVita by 731.6% in the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after purchasing an additional 108,446 shares during the last quarter. JPMorgan Chase & Co. increased its position in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the period. KBC Group NV raised its stake in DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after purchasing an additional 67,250 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of DaVita in the third quarter valued at approximately $10,346,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DVA. Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Truist Financial boosted their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Stock Up 0.4 %

NYSE:DVA opened at $176.93 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The stock has a 50-day moving average price of $159.91 and a two-hundred day moving average price of $155.57. DaVita has a 1 year low of $108.76 and a 1 year high of $179.60. The stock has a market cap of $14.51 billion, a price-to-earnings ratio of 19.09, a PEG ratio of 0.86 and a beta of 0.93.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.